Skip to main content

Table 4 Comparison of genetic variants and other risk factors in patients with different grades of hepatic steatosis after liver transplantation

From: Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study

Univariate

Multivariate analysis

 

Moderate to severe steatosis

Mild steatosis

P value

OR

95% CI

P value

Age (year)

51.90 ± 9.94

47.41 ± 11.27

0.207

   

Sex (male/female)

10/10

13/4

0.098

   

Height (cm)

167.10 ± 11.55

169.41 ± 9.23

0.511

   

Weight (kg)

86 ± 16.89

74.76 ± 16.47

0.049

   

BMI (kg/m2)

30.81 ± 5.11

25.99 ± 5.38

0.008

1.055

0.855–1.301

0.620

WC (cm)

109.74 ± 11.74

99.29 ± 9.95

0.006

1.062

0.953–1.183

0.276

AST (IU/L)

21.62 ± 9.4

23.92 ± 13.61

0.590

   

ALT (IU/L)

24.43 ± 11.76

26.57 ± 13.74

0.650

   

PTDM

57.9%

64.7%

0.676

   

Post-transplant HLP

47.4%

47.1%

0.985

   

Post-transplant HTN

42.1%

35.3%

0.676

   

Rejection

36.7%

34.5%

0.839

   

Mean prednisolone dose (mg)

8.26 ± 3.87

7.20 ± 3.74

0.379

   

TM6SF2 genotype

 CT + TT versus CC

75%

76.5%

0.917

   

PCSK9 genotype

 AG + GG versus AA

65%

17.6%

0.004

5.747

1.086–30.303

0.040

PCSK7 genotype

 CT + TT versus CC

65%

88.2%

0.101

   
  1. BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, PTDM post-transplant diabetes mellitus, HLP hyperlipidemia, HTN hypertension, WC waist circumference, HC hip circumference, TM6SF2 transmembrane 6 super family 2, PCSK9 proprotein convertase subtilisin/kexin type 9, PCSK7 proprotein convertase subtilisin/kexin type 7